Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain H Rook

Showing results (31-40 of 98) with videos related to

Pageof 10
Sort By:
Journal of the American Academy of Dermatology|October 5, 2010
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphomaYoun H Kim, Michael Girardi, Madeleine Duvic, et al.
Archives of Dermatology|August 20, 2008
CD8+ epidermotropic cytotoxic T-cell lymphoma with peripheral blood and central nervous system involvementCamille E Introcaso, Ellen J Kim, Jennifer Gardner, et al.
Blood|March 4, 2008
Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expressionEmmanuel Contassot, Katrin Kerl, Stéphanie Roques, et al.
The Journal of Investigative Dermatology|February 14, 2002
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphomaMohamed H Zaki, Maria Wysocka, Suzanne E Everetts, et al.
Archives of Dermatology|March 23, 2005
Biological effects of bexarotene in cutaneous T-cell lymphomaJeanne B Budgin, Stephen K Richardson, Sarah B Newton, et al.
Acta Dermato-Venereologica|March 23, 2016
Cutaneous T-cell Lymphoma and Pruritus: The Expression of IL-31 and its Receptors in the SkinLeigh A Nattkemper, Maria-Estela Martinez-Escala, Ari B Gelman, et al.
American Journal of Hematology|March 13, 2008
Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosisAndrew B Avarbock, Alison W Loren, Jason Y Park, et al.
Blood|August 19, 2004
Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sézary syndrome: circumvention by hexameric soluble CD40LLars E French, Bertrand Huard, Maria Wysocka, et al.
Clinical Lymphoma & Myeloma|January 19, 2007
High clinical response rate with multimodality immunomodulatory therapy for Sézary syndromeStephen K Richardson, Julie H Lin, Carmela C Vittorio, et al.
The Journal of Investigative Dermatology|July 5, 2022
The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ΔNp73 DepletionLei Zhao, Tony Hsiao, Connor Stonesifer, et al.
Pageof 10

Showing results (31-40 of 98) with videos related to

Sort By:
Pageof 10
Journal of the American Academy of Dermatology|October 5, 2010
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphomaYoun H Kim, Michael Girardi, Madeleine Duvic, et al.
Archives of Dermatology|August 20, 2008
CD8+ epidermotropic cytotoxic T-cell lymphoma with peripheral blood and central nervous system involvementCamille E Introcaso, Ellen J Kim, Jennifer Gardner, et al.
Blood|March 4, 2008
Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expressionEmmanuel Contassot, Katrin Kerl, Stéphanie Roques, et al.
The Journal of Investigative Dermatology|February 14, 2002
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphomaMohamed H Zaki, Maria Wysocka, Suzanne E Everetts, et al.
Archives of Dermatology|March 23, 2005
Biological effects of bexarotene in cutaneous T-cell lymphomaJeanne B Budgin, Stephen K Richardson, Sarah B Newton, et al.
Acta Dermato-Venereologica|March 23, 2016
Cutaneous T-cell Lymphoma and Pruritus: The Expression of IL-31 and its Receptors in the SkinLeigh A Nattkemper, Maria-Estela Martinez-Escala, Ari B Gelman, et al.
American Journal of Hematology|March 13, 2008
Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosisAndrew B Avarbock, Alison W Loren, Jason Y Park, et al.
Blood|August 19, 2004
Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sézary syndrome: circumvention by hexameric soluble CD40LLars E French, Bertrand Huard, Maria Wysocka, et al.
Clinical Lymphoma & Myeloma|January 19, 2007
High clinical response rate with multimodality immunomodulatory therapy for Sézary syndromeStephen K Richardson, Julie H Lin, Carmela C Vittorio, et al.
The Journal of Investigative Dermatology|July 5, 2022
The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ΔNp73 DepletionLei Zhao, Tony Hsiao, Connor Stonesifer, et al.
Pageof 10